## Abstract ## BACKGROUND. The American Joint Committee on Cancer (AJCC) staging system for prostate cancer is based primarily based on clinical tumor (T) classification. In this article, the authors summarize arguments for incorporating additional pretreatment parameters and creating a new stagin
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer
โ Scribed by William D. Figg; Michael E. Franks; David Venzon; Paul Duray; Michael C. Cox; W. Marston Linehan; W. Van Bingham; James A. Eastham; Eddie Reed; Oliver Sartor
- Publisher
- Springer-Verlag
- Year
- 2004
- Tongue
- English
- Weight
- 230 KB
- Volume
- 22
- Category
- Article
- ISSN
- 0724-4983
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Background: Prostate-specific antigen (psa) is a good objective measure of tumor cell burden or virulence of disease, or both, in prostate cancer. many differences between whites and african americans (aa) have been noted in prostate cancer in the united states, including a poorer outcome in afr
## BACKGROUND. The routine use of serum prostate-specific antigen (PSA) testing combined with digital rectal examination has lowered tumor volume and clinical-pathological stage of men undergoing radical prostatectomy. Therefore, we may identify more men with poorly differentiated tumors of early